Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

25.800
+0.4001.57%
Volume:6.72M
Turnover:173.89M
Market Cap:22.50B
PE:27.99
High:26.800
Open:25.300
Low:24.750
Close:25.400
Loading ...

BRIEF-Hutchmed Says Tagrisso Plus Orpathys Demonstrated Clinically Meaningful Response Rate In Lung Cancer Patients

Reuters
·
16 Oct 2024

HUTCHMED China Ltd - Savannah: Clinically Meaningful Response Rate

THOMSON REUTERS
·
16 Oct 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

GlobeNewswire
·
16 Oct 2024

HUTCHMED (China)- Announces That Tagrisso Plus Orpathys Demonstrated High, Clinically Meaningful Response Rate in Lung Cancer Patients

THOMSON REUTERS
·
16 Oct 2024

Hutchmed's Partner Takeda Pharmaceutical Gets Go-Ahead to Produce, Market Colorectal Cancer Drug in Japan

MT Newswires Live
·
24 Sep 2024

BRIEF-Hutchmed (China) Says Takeda Receives Approval From Japan Ministry Of Health, Labour, Welfare

Reuters
·
24 Sep 2024

BRIEF-Hutchmed China Announces Partner Takeda's Japan Approval For Fruzaqla

Reuters
·
24 Sep 2024

HUTCHMED (China) - Takeda Received Approval From Japanese Ministry of Health, Labour and Welfare

THOMSON REUTERS
·
24 Sep 2024

HUTCHMED (China) - Approval to Manufacture and Market Fruzaqla for Previously Treated Metastatic Colorectal Cancer

THOMSON REUTERS
·
24 Sep 2024

HUTCHMED China Ltd - Japan Approval for Fruzaqla

THOMSON REUTERS
·
24 Sep 2024

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

GlobeNewswire
·
24 Sep 2024

Stock Track | HUTCHMED Soars as UK Approves Cancer Drug Fruquintinib

Stock Track
·
20 Sep 2024

BRIEF-UK'S MHRA Approves Fruquintinib To Treat Adult Patients With Metastatic Colorectal Cancer

Reuters
·
20 Sep 2024

UK's Mhra: Fruquintinib Approved to Treat Adult Patients With Metastatic Colorectal Cancer

THOMSON REUTERS
·
20 Sep 2024

- HUTCHMED China Ltd - Clinical Data to Be Presented at Esmo and Wclc

THOMSON REUTERS
·
09 Sep 2024

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

GlobeNewswire
·
09 Sep 2024